Smoked drug use in patients with TB is associated with higher bacterial burden
Bronwyn Myers, Tara Carney, James F. Rooney, Samantha Malatesta, Elizabeth J. Ragan, Laura F. White, Hristina Natcheva, Tara C. Bouton, S. E. Weber, Maha Farhat, Helen McIlleron, D. Theron, Charles Parry, C. Robert Horsburgh, Robin M. Warren, Karen R. Jacobson
Abstract
BACKGROUND: Smoking of illicit drugs may lead to more rapid TB disease progression or late treatment presentation, yet research on this topic is scant. We examined the association between smoked drug use and bacterial burden among patients newly initiated on drug-susceptible TB (DS-TB) therapy. METHODS: Data from 303 participants initiating DS-TB treatment in the Western Cape Province, South Africa, were analyzed. Smoked drug use was defined as self-reported or biologically verified methamphetamine, methaqualone and/or cannabis use. Proportional hazard and logistic regression models (adjusted for age, sex, HIV status and tobacco use) examined associations between smoked drug use and mycobacterial time to culture positivity (TTP), acid-fast bacilli sputum smear positivity and lung cavitation. RESULTS: People who smoked drugs (PWSD) comprised 54.8% ( n = 166) of the cohort. TTP was faster for PWSD (hazard ratio 1.48, 95% CI 1.10–1.97; P = 0.008). Smear positivity was higher among PWSD (OR 2.28, 95% CI 1.22–4.34; P = 0.011). Smoked drug use (OR 1.08, 95% CI 0.62–1.87; P = 0.799) was not associated with increased cavitation. CONCLUSIONS: PWSD had a higher bacterial burden at diagnosis than those who do not smoke drugs. Screening for TB among PWSD in the community may facilitate earlier linkage to TB treatment and reduce community transmission.